D-Wave's $100M Catalyst: Still an LOI as Weak Fundamentals Persist

What happened

D-Wave Quantum Inc. (QBTS) received a $100 million Letter of Intent from the Department of Commerce under the CHIPS Act, which the market has treated as a massive catalyst. However, as of the latest SEC filings, this award remains a non-binding proposal, with the only quantified federal funding being a $1.6 million NSF grant. Meanwhile, D-Wave's Q1 2026 revenue collapsed to $2.9 million (down 81% year-over-year), driven by zero system sales, and operating cash burn reached $45 million. The company's $8.8 billion market cap implies a valuation detached from underlying business reality, with heavy reliance on unproven gate-model revenue and potential dilution from the CHIPS equity-for-cash structure. Insider selling by the CEO and CFO in May and June 2026 further signals lack of confidence in near-term execution.

Implication

The market is pricing in a $100M CHIPS award that is still just a letter of intent, and the company's business is deteriorating: Q1 revenue fell 81% YoY to $2.9M, system sales were negligible, and cash burn remains high at $45M per quarter. The $8.8B market cap implies a forward revenue multiple that utterly ignores the risk of dilution (CHIPS likely to involve equity issuance) and the uncertainty around gate-model monetization. Insider selling by the CEO and CFO in the weeks after the CHIPS announcement further undercuts management's public optimism. Our base case values the stock at $24, but we see material downside to $16 if award documentation stalls and burn continues. Investors should not buy this thesis until we see a definitive award with favorable economics and tangible commercial traction in QCaaS or gate-model revenue.

Thesis delta

The DeepValue report flagged QBTS as a potential sell due to the CHIPS LOI being non-binding and weak Q1 results. The Fool article's hype around a 'massive $100 million catalyst' does not align with the reality that the LOI is not a definitive award. Our thesis shifts from wait-and-see to outright skepticism—the underlying business is deteriorating, and the catalyst is overhyped.